As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.
Ergomed appoints Roy Ovel
AppointmentsErgomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.
EMA recommends bluebird’s ?-thalassemia gene therapy
Latest NewsThe European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
No Games. Just Deals!
BackgroundAs resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.
Selvita to spin out cancer business
Latest NewsKrakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.
Polyneuron Pharma raise CHF22.5m in Series A financing
Latest NewsThe CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
Genfit prices IPO at $135m
Latest NewsFrench liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
Evotec partners with Mark Foundation for Cancer Research
Latest NewsHookipa Pharma files for US-$86m IPO
Latest NewsUS-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO.
Neophore appoints Dr John Haurum
AppointmentsNeophore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect.
SPC manufacturing waivers: A blow to innovation?
BackgroundThe EU’s Big Pharma companies have sharply criticised the European Parliament’s Legal Committee JURI backing of an amended proposal of the European Commission (EC) to introduce a supplementary protection certificates (SPC) manufacturing waiver. Under the waiver, EU-based biosimilar and generics makers would be allowed to export copycat drugs during the SPC period that adds five years of additional IP protection to the 20 years of patent duration.